| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.69 M USD | -8.50 M USD | -9.14 M USD | -8.41 M USD | -2.95 M USD | -3.51 M USD | -4.62 M USD | -2.55 M USD | -4.67 M USD | -6.56 M USD | -2.53 M USD | -9.09 M USD |
| Depreciation & Amortization | 626000 USD | 587000 USD | 595000 USD | 429000 USD | 105653 USD | 126211 USD | 122736 USD | 513029 USD | 554361 USD | 367611 USD | 320301 USD | 413773 USD |
| Stock-Based Compensation | 9.85 M USD | 10.26 M USD | 10.62 M USD | 10.58 M USD | 9.36 M USD | 3.17 M USD | 1.33 M USD | 560973 USD | 768682 USD | 1.37 M USD | 1.31 M USD | 1.50 M USD |
| Capital Expenditures | 93000 USD | 34000 USD | 366000 USD | 2.38 M USD | 1.40 M USD | 70896 USD | 29486 USD | 265482 USD | 81577 USD | 410184 USD | — | — |
| Cash Flow from Investing | -93000 USD | 74000 USD | 19.77 M USD | -22.09 M USD | -1.40 M USD | -70896 USD | -29486 USD | -265482 USD | -81577 USD | -410184 USD | -153151 USD | -123912 USD |
| Cash Flow from Financing | 14.76 M USD | 297000 USD | 81000 USD | 220000 USD | 547411 USD | 17.34 M USD | 24.03 M USD | 9.92 M USD | -58946 USD | 9.88 M USD | 1.00 M USD | 2.71 M USD |
| Dividends Paid | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD | — | — | 0 USD | 0 USD | 0 USD | 0 USD |
| Stock Buybacks | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | -13.78 M USD | -8.53 M USD | -9.51 M USD | -10.79 M USD | -4.34 M USD | -3.58 M USD | -4.65 M USD | -2.81 M USD | -4.76 M USD | -6.97 M USD | — | — |
Stereotaxis Inc. is a cutting-edge medical technology company that specializes in robotic systems for minimally invasive surgery. The company's primary focus is on the development and commercialization of robotic navigation technologies designed to enhance the precision, safety, and efficiency of procedures within the cardiac arrhythmia treatment sector. Stereotaxis' flagship product, the Niobe Magnetic Navigation System, enables physicians to maneuver catheters with a high degree of accuracy, using magnetic fields to decrease potential complications associated with traditional manual techniques. This technology significantly impacts the healthcare sector, particularly hospitals and medical centers specializing in interventional cardiology, by improving patient outcomes and operational workflows. Based in St. Louis, Missouri, Stereotaxis plays a significant role in advancing the field of robotic surgery, contributing to the broader medical device market's growth and innovation.